These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 37259012)
1. Targeting Sigma-1 Receptor: A Promising Strategy in the Treatment of Parkinson's Disease. Siddiqui T; Bhatt LK Neurochem Res; 2023 Oct; 48(10):2925-2935. PubMed ID: 37259012 [TBL] [Abstract][Full Text] [Related]
2. Neuroinflammation in Parkinson's Disease and its Treatment Opportunities. Çınar E; Tel BC; Şahin G Balkan Med J; 2022 Sep; 39(5):318-333. PubMed ID: 36036436 [TBL] [Abstract][Full Text] [Related]
3. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review. Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973 [TBL] [Abstract][Full Text] [Related]
5. The interplay between neuroinflammatory pathways and Parkinson's disease. Eser P; Kocabicak E; Bekar A; Temel Y Exp Neurol; 2024 Feb; 372():114644. PubMed ID: 38061555 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent Perspectives. Sarkar S; Raymick J; Imam S Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338353 [TBL] [Abstract][Full Text] [Related]
7. Uncovering Novel Therapeutic Targets for Parkinson's Disease. Soni R; Delvadia P; Joharapurkar A; Shah J ACS Chem Neurosci; 2023 Jun; 14(11):1935-1949. PubMed ID: 37227448 [TBL] [Abstract][Full Text] [Related]
8. The role of Toll-like receptors and neuroinflammation in Parkinson's disease. Heidari A; Yazdanpanah N; Rezaei N J Neuroinflammation; 2022 Jun; 19(1):135. PubMed ID: 35668422 [TBL] [Abstract][Full Text] [Related]
10. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit. Tozzi A; Sciaccaluga M; Loffredo V; Megaro A; Ledonne A; Cardinale A; Federici M; Bellingacci L; Paciotti S; Ferrari E; La Rocca A; Martini A; Mercuri NB; Gardoni F; Picconi B; Ghiglieri V; De Leonibus E; Calabresi P Brain; 2021 Dec; 144(11):3477-3491. PubMed ID: 34297092 [TBL] [Abstract][Full Text] [Related]
11. Vitamin E Analog Trolox Attenuates MPTP-Induced Parkinson's Disease in Mice, Mitigating Oxidative Stress, Neuroinflammation, and Motor Impairment. Atiq A; Lee HJ; Khan A; Kang MH; Rehman IU; Ahmad R; Tahir M; Ali J; Choe K; Park JS; Kim MO Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373089 [TBL] [Abstract][Full Text] [Related]
12. CD8 T cell nigral infiltration precedes synucleinopathy in early stages of Parkinson's disease. Galiano-Landeira J; Torra A; Vila M; Bové J Brain; 2020 Dec; 143(12):3717-3733. PubMed ID: 33118032 [TBL] [Abstract][Full Text] [Related]
13. The understanding of Parkinson's disease through genetics and new therapies. Uwishema O; Onyeaka H; Badri R; Yücel AN; Korkusuz AK; Ajagbe AO; Abuleil A; Chaaya C; Alhendawi BHM; Chalhoub E Brain Behav; 2022 May; 12(5):e2577. PubMed ID: 35451243 [TBL] [Abstract][Full Text] [Related]
14. Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein. Elgueta D; Chovar O; Ugalde V; Sánchez-Guajardo V; Catenaccio A; Court F; Pacheco R J Vis Exp; 2022 Jul; (185):. PubMed ID: 35969046 [TBL] [Abstract][Full Text] [Related]
15. The Intranigral Infusion of Human-Alpha Synuclein Oligomers Induces a Cognitive Impairment in Rats Associated with Changes in Neuronal Firing and Neuroinflammation in the Anterior Cingulate Cortex. Palmas MF; Etzi M; Pisanu A; Camoglio C; Sagheddu C; Santoni M; Manchinu MF; Pala M; Fusco G; De Simone A; Picci L; Mulas G; Spiga S; Scherma M; Fadda P; Pistis M; Simola N; Carboni E; Carta AR Cells; 2022 Aug; 11(17):. PubMed ID: 36078036 [TBL] [Abstract][Full Text] [Related]
16. Parkinson's Disease: Exploring Different Animal Model Systems. Khan E; Hasan I; Haque ME Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240432 [TBL] [Abstract][Full Text] [Related]
17. Age and Parkinson's disease-related neuronal death in the substantia nigra pars compacta. Eriksen N; Stark AK; Pakkenberg B J Neural Transm Suppl; 2009; (73):203-13. PubMed ID: 20411779 [TBL] [Abstract][Full Text] [Related]
18. Targeting alpha-synuclein via the immune system in Parkinson's disease: Current vaccine therapies. Fleming SM; Davis A; Simons E Neuropharmacology; 2022 Jan; 202():108870. PubMed ID: 34742741 [TBL] [Abstract][Full Text] [Related]
19. Suppression of neuroinflammation and α-synuclein oligomerization by rotarod walking exercise in subacute MPTP model of Parkinson's disease. Leem YH; Park JS; Park JE; Kim DY; Kim HS Neurochem Int; 2023 May; 165():105519. PubMed ID: 36931345 [TBL] [Abstract][Full Text] [Related]
20. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice. Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]